An estimation of the prevalence of opioid dependence in New Zealand
An estimation of the prevalence of opioid dependence in New Zealand
复制标题
DOI：
10.1016/j.drugpo.2011.05.013
复制
发表时间：
2012-01-01
影响因子：
4.4
通讯作者：
Frampton, Chris M. A.
中科院分区：
文献类型：
--
作者：
Adamson, Simon J.;Deering, Daryle E. A.;Frampton, Chris M. A.
背景：缺乏对新西兰阿片类药物依赖的准确患病率以及未满足治疗需求的程度的估计。方法：通过滚雪球抽样招募阿片类药物使用者，参与者最初是从奥克兰的阿片类药物替代治疗 (OST) 服务和专门的针具交换所招募的。陶朗加和基督城。参与者估计了他们认识的接受 OST 和未接受 OST 但每天或几乎每天使用阿片类药物的人数。根据这些估计值，得出这两组之间的比率乘数，并将其应用于新西兰接受 OST 的已知人数，以得出总人口估计值。结果：84 名招募的参与者的平均乘数估计值（根据治疗地点加权）为 2.015。基督城的乘数更高。初始招聘来源不影响乘数估计值。当将乘数应用于新西兰 OST 治疗人口的已知规模时，阿片类药物依赖人口总数估计为 9142 人（95% CI：8248-10036），其中一半人没有接受 OST。 结论：该数字低于之前不太稳健的估计，但仍代表大量未满足的需求。需要付出更大的努力来缩小这一治疗差距。 (C) 2011 Elsevier B.V. 保留所有权利。
Background: An accurate prevalence estimate for opioid dependence in New Zealand, and hence the extent of unmet treatment need, is lacking.Methods: Opioid users were recruited via snowball sampling, with participants initially recruited from opioid substitution treatment (OST) services and dedicated needle exchanges in Auckland. Tauranga and Christchurch. Participants estimated the number of people they knew personally who were receiving OST and who were not receiving OST, but were using opioids daily or almost daily. From these estimates a multiplier of the ratio between these two groups was derived and applied to the known number receiving OST in New Zealand to arrive at the total population estimate.Results: The mean multiplier estimate, weighted for treatment site, for 84 recruited participants was 2.015. The multiplier was higher for Christchurch. Initial recruitment source did not influence the value of the multiplier estimate. When the multiplier was applied to the known size of the New Zealand OST treatment population the total opioid dependent population was estimated to be 9142(95% CI: 8248-10036), of whom half were not receiving OST.Conclusion: This figure was lower than for previous less robust estimates, but still represents a substantial level of unmet need. Greater effort needs to be made to close this treatment gap. (C) 2011 Elsevier B.V. All rights reserved.